Startup profile for Alleviate Health: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Alleviate Health funding, valuation and investors

AI recruiter automating patient enrollment for clinical research sites.

Keep track of Alleviate Health

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Seed

$4.3M · October 2025

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$4.3M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

seed · Durham, NC

Investors in latest funding

Lead: Andreessen Horowitz

Sources: latest funding Last verified: 2026-07-25

Overview

Alleviate Health provides an AI-powered recruitment platform for clinical research sites. Its human-in-the-loop agents engage potential trial participants 24/7 via SMS and voice, screen against protocol eligibility, schedule visits, and escalate to human recruiters when needed. The product includes a clinical-research-specific CRM that captures patient preferences and interaction history. Founded in 2023 and headquartered in Durham, North Carolina, Alleviate publicly launched in October 2025 after raising a $4.3M seed round led by Andreessen Horowitz. The company reports working with seven of the top 15 U.S. site networks and handling 500,000+ patient interactions across 190+ sites and 300+ trials in its first year of operations.

Why Alleviate Health is interesting

Human-in-the-loop SMS and voice agents already run at 190+ sites — Alleviate attacks the site-level recruitment bottleneck that delays trials, not sponsor-side ad spend.

Product & use cases

Alleviate deploys SMS and voice AI agents that pre-screen trial candidates, book on-site visits, and hand off qualified leads to site recruiters — integrated with CTMS/CRM systems sites already use.

  • High-volume outbound patient outreach for multi-site trial recruitment
  • Protocol-based pre-screening via SMS before CRC visits
  • Voice-AI pre-qualification with warm transfer to human recruiters

Key facts

  • Seed (Oct 2025): $4.3M led by a16z (Business Wire)
  • Live at 190+ sites in U.S. and Canada; 500k+ patient interactions in first year
  • Customers include Alcanza, CenExel, M3 Wake, Centricity, Eximia among top site networks
  • Co-investors not in VCT directory: Alt Capital, First Harmonic

Funding history (newest first)

Investors in our directory

Funds linked from Alleviate Health's profile — open a fund page for stage focus and related deal articles.

Competitive landscape

Edge: Site-network distribution (7 of top 15 U.S. networks) and 500k+ interaction training data give Alleviate workflow depth across indications vs. generic conversational AI tools.

Clinical trial recruitment splits between sponsor-side patient finding (EHR analytics, DTC ads) and site-level operational bottlenecks. Alleviate targets the latter — where coordinators manually call thousands of leads — with agents trained across 300+ trials. Competitors like Antidote and StudyPages focus more on patient discovery and marketing. Site networks' willingness to adopt human-in-the-loop AI (vs. full replacement) is the product bet; early scale across top networks is the traction signal.

  • Antidote direct

    Patient-matching and recruitment marketing for trials; Alleviate focuses on site-operational workflows and CRM integration.

  • Deep 6 AI adjacent

    EHR-based patient finding for health systems; Alleviate targets site recruiter operations and outbound engagement.

  • TrialSpark / similar CRO tools adjacent

    Full-service and hybrid models; Alleviate sells software agents to existing site staff.

  • Manual site recruiter teams incumbent

    Default approach — phone tag and fragmented systems; Alleviate automates repetitive pre-screening while keeping humans for conversion.

Notable stories

  • Alleviate taped customer feedback from recruiter Haley McSweeney on its office wall — she said AI removes pre-screening drudgery but won't replace human connection needed for trial enrollment (company LinkedIn launch post).
  • The a16z deal was a collaboration between Apps and Bio/Health teams per partner Marc Andrusko — reflecting cross-practice interest in vertical AI agents.
  • Founders built the product while embedded with site networks, optimizing messaging across 'every possible patient population, indication, and workflow' before public launch.

Industries

Healthtech AI & Machine Learning

Related funding articles

Venture Capital Tracker pieces that cover Alleviate Health's financing or category context.

FAQs about Alleviate Health

Practical answers founders, operators, and investors typically search for.

Alleviate Health provides AI recruiters for clinical research sites — SMS and voice agents that outreach patients, pre-screen against trial protocols, schedule visits, and hand qualified leads to human coordinators.
Andreessen Horowitz led the $4.3M seed round in October 2025. Alt Capital and First Harmonic also participated. See /fund/andreessen-horowitz.
Alleviate reported 190+ sites in the U.S. and Canada at launch, including seven of the top 15 U.S. site networks.
No. Alleviate uses human-in-the-loop workflows — AI handles repetitive outreach and pre-screening; recruiters take over for conversion-critical conversations.
Antidote focuses on patient matching and recruitment marketing. Alleviate embeds in site operations with SMS/voice agents and a site-specific CRM for day-to-day coordinator workflows.
SMS and voice AI for patient engagement, with integrations to CTMS and CRM systems sites already operate.
The company was founded in 2023 and publicly launched in October 2025 alongside its seed funding announcement.
Durham, North Carolina, with team presence in San Francisco per company profiles.
Alleviate has not disclosed profitability. It raised a $4.3M seed in 2025 and is scaling across U.S. and Canadian site networks.
The company claims agents respond in under 10 seconds after a patient expresses interest, improving conversion to on-site visits.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.